```html

Klebsiella pneumoniae Carbapenem‑Resistant Infection

Overview

Klebsiella pneumoniae is a gram‑negative, rod‑shaped bacterium that normally lives in the gastrointestinal tract and on the skin of healthy people. Certain strains have acquired genes that make them resistant to carbapenems—broad‑spectrum antibiotics often used as a “last resort.” When these carbapenem‑resistant Klebsiella pneumoniae (CRKP) strains cause disease, they are referred to as Klebsiella pneumoniae carbapenem‑resistant infection.

CRKP infections are most common in hospitals and long‑term care facilities, where antibiotics are used heavily and vulnerable patients congregate. In the United States, the Centers for Disease Control and Prevention (CDC) estimates that approximately 13,000 CRKP infections occur each year, resulting in 1,100–1,500 deaths. Worldwide, surveillance data from the World Health Organization (WHO) suggest that carbapenem‑resistant Enterobacteriaceae (CRE), of which CRKP is a leading cause, affect more than 50,000 patients annually in Europe alone, with a mortality rate ranging from 30‑50 % in high‑risk groups【1】.

People of any age can be infected, but the highest risk groups include:

• Patients in intensive care units (ICU) or on mechanical ventilation
• Individuals with recent or prolonged antibiotic use
• Those with invasive devices (central lines, urinary catheters, feeding tubes)
• Patients with weak immune systems (e.g., chemotherapy, transplant recipients, HIV/AIDS)
• Residents of long‑term care facilities

Symptoms

CRKP can cause many types of infection, each with its own constellation of signs. The most common presentations are:

• Bloodstream infection (sepsis) – fever, chills, rapid heartbeat, low blood pressure, confusion, or organ dysfunction.
• Pneumonia – cough, thick or bloody sputum, chest pain, shortness of breath, fever, and fatigue.
• Urinary tract infection (UTI) – burning on urination, frequent urge to urinate, cloudy or foul‑smelling urine, flank pain, fever.
• Wound or surgical site infection – redness, swelling, warmth, pus or foul odor from the wound, fever.
• Intra‑abdominal infection – abdominal pain, tenderness, nausea, vomiting, fever, and sometimes ileus (bowel paralysis).

Because CRKP is resistant to many antibiotics, symptoms often persist or worsen despite standard treatment, which is a key clinical clue.

Causes and Risk Factors

What causes CRKP infection?

CRKP infections arise when the bacterium acquires carbapenem‑resistance genes, most commonly KPC (Klebsiella pneumoniae carbapenemase), NDM (New Delhi metallo‑β‑lactamase), VIM, or OXA‑48. These genes are carried on plasmids—small DNA fragments that can jump between bacteria—making resistance spread rapidly within hospitals.<sup>2</sup>

Key risk factors

• Recent hospitalization or surgery – especially stays >5 days.
• Use of broad‑spectrum antibiotics (carbapenems, third‑generation cephalosporins, fluoroquinolones) within the past 90 days.
• Invasive medical devices – central venous catheters, urinary catheters, endotracheal tubes, feeding tubes.
• Intensive care unit (ICU) admission – higher exposure to resistant organisms.
• Immunosuppression – chemotherapy, organ transplant, chronic steroids.
• Living in a long‑term care facility – higher colonization rates (up to 15 % in some facilities).
• Previous colonization with CRE – colonization often precedes infection.

Diagnosis

Prompt, accurate diagnosis is crucial because delays increase mortality. The diagnostic pathway typically includes:

1. Clinical assessment

Physicians evaluate signs of infection, recent exposures, and risk factors. A high index of suspicion is maintained for patients who fail to improve on standard antibiotics.

2. Microbiologic cultures

• Blood cultures – drawn before antibiotics if possible; at least two sets are recommended.
• Sputum, urine, wound, or body‑fluid cultures – depending on the suspected infection site.

3. Antimicrobial susceptibility testing (AST)

Laboratories perform broth microdilution or automated systems (e.g., VITEK 2) to determine resistance to carbapenems and other agents. The presence of a carbapenemase is confirmed with:

• Carbapenem Inactivation Method (CIM) or Modified Hodge Test
• Molecular assays – PCR for KPC, NDM, VIM, OXA‑48 genes (highly sensitive and rapid)
• Whole‑genome sequencing – used in outbreak investigations.

4. Imaging studies

Depending on the infection site:

• Chest X‑ray or CT scan for pneumonia.
• Abdominal CT for intra‑abdominal infections.
• Ultrasound for complicated urinary infections.

5. Infection control screening

Hospitals often perform rectal swab cultures to identify colonized patients, allowing isolation precautions to prevent spread.

Treatment Options

Because CRKP is resistant to many drugs, therapy must be individualized based on susceptibility results, infection severity, and patient factors.

1. Antimicrobial therapy

Current guidelines (IDSA, 2022) recommend a combination regimen for serious infections:

• Newer β‑lactam/β‑lactamase inhibitor combinations –
  • Ceftazidime‑avibactam (active against KPC‑producing strains)
  • Meropenem‑vaborbactam (effective for KPC, some OXA‑48)
• Polymyxins – colistin or polymyxin B (used when newer agents are unavailable or resistance is present). Monitoring for nephro‑ and neuro‑toxicity is essential.
• Tigecycline – an option for bloodstream infections when the isolate is susceptible; dosing must be high‑dose (100 mg q12h) to achieve adequate serum levels.
• Fosfomycin – oral formulation can be used for uncomplicated urinary infections caused by susceptible CRKP.
• Gentamicin or amikacin – considered if the isolate shows aminoglycoside susceptibility.

Combination therapy (e.g., ceftazidime‑avibactam + aztreonam for NDM‑producing strains) improves bactericidal activity and reduces emergence of further resistance.

2. Source control

Eradicating the nidus of infection is often as important as antibiotics:

• Removal of infected catheters or lines.
• Drainage of abscesses or empyemas.
• Debridement of necrotic tissue in wound infections.
• Appropriate surgical intervention for intra‑abdominal infections.

3. Supportive care

For sepsis or severe pneumonia, patients may require:

• Intravenous fluids and vasopressors
• Mechanical ventilation
• Renal replacement therapy if nephrotoxic drugs cause kidney injury

4. Lifestyle and adjunct measures

• Optimization of nutrition (high‑protein diet, consider supplements if malnourished).
• Strict glycemic control for diabetic patients.
• Physical therapy to maintain functional status during prolonged hospital stays.

Living with Klebsiella pneumoniae Carbapenem‑Resistant Infection

Even after the acute phase, many patients face challenges that require ongoing attention.

• Medication adherence – Take the full course of prescribed antibiotics, even if you feel better.
• Follow‑up appointments – Repeat cultures are often needed to confirm eradication.
• Monitoring for side effects – Report new kidney problems, hearing changes, or skin rashes promptly.
• Home hygiene – Hand washing with soap for at least 20 seconds, regular cleaning of high‑touch surfaces, and proper disposal of dressings.
• Vaccinations – Stay up‑to‑date with influenza and pneumococcal vaccines to reduce secondary infections.
• Psychological support – Chronic infection can cause anxiety; consider counseling or support groups.

Prevention

Preventing CRKP spread relies on both healthcare‑setting measures and personal habits.

In healthcare facilities

• Contact precautions for colonized/infected patients (gown, gloves, dedicated equipment).
• Active surveillance cultures on admission to high‑risk units.
• Antimicrobial stewardship programs to limit unnecessary carbapenem use.
• Environmental cleaning with EPA‑approved disinfectants effective against gram‑negative organisms.
• Education of staff on hand hygiene and proper catheter care.

For patients and families

• Wash hands frequently, especially after touching any medical device.
• Ask clinicians about the necessity of each antibiotic; avoid pressuring for “stronger” drugs.
• Maintain up‑to‑date vaccinations.
• Stay informed about any colonization status; inform new healthcare providers of past CRKP infection.

Complications

If CRKP infection is not promptly and adequately treated, serious complications can develop:

• Septic shock – life‑threatening drop in blood pressure requiring vasopressors.
• Acute respiratory distress syndrome (ARDS) – severe pneumonia can progress to lung failure.
• Renal failure – either from sepsis or nephrotoxic antibiotics.
• End‑organ damage – heart, liver, or brain dysfunction due to prolonged low perfusion.
• Persistent colonization – patients may become chronic carriers, increasing future infection risk and transmission to contacts.
• Mortality – reported 30‑day mortality rates range from 30 % to 50 % in critically ill patients with bloodstream infection【3】.

When to Seek Emergency Care

References

1. World Health Organization. Global Antimicrobial Resistance Surveillance System (GLASS) Report 2023. WHO; 2023.
2. Pitout JD, Nordmann P. “KPC‑producing Klebsiella pneumoniae: a story of plasmid-mediated carbapenem resistance.” Lancet Infect Dis. 2020;20(5):eFrome‑e203.
3. Centers for Disease Control and Prevention. “Carbapenem‑Resistant Enterobacteriaceae (CRE) Infections.” Updated 2024. https://www.cdc.gov/hai/organisms/cre/cre.html
4. Infectious Diseases Society of America. “Clinical Practice Guidelines for the Treatment of Multidrug‑Resistant Gram‑Negative Bacterial Infections.” 2022.
5. Mayo Clinic. “Klebsiella infection.” Updated 2024. https://www.mayoclinic.org

```